Ricevi le ultime notizie sulle azioni CERo Therapeutics Hldgs con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CERO

Ultime notizie per

CERO THERAPEUTICS HOLDINGS I

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

Press Releases

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

General

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

News

Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

BGSF

CERO

INEO

PCSA

PNPNF

PRPH

PRSO

SAFX

SNYR

TSXV:PNPN

XTIA

AIM ImmunoTech

Aprea Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Ensysce Biosciences

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Comments

CERo Therapeutics Hldgs Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO